Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report?

Core Insights - CRISPR Therapeutics AG reported a narrower-than-expected loss in Q3 2025, with a loss of $1.17 per share compared to the Zacks Consensus Estimate of a loss of $1.32 [2] - Total revenues for the quarter were $0.9 million, significantly missing the consensus estimate of $6.7 million, although this was an increase from $0.6 million in the same quarter last year [3] Financial Performance - Research and development (R&D) expenses decreased by 28% year-over-year to $58.9 million, attributed to reduced manufacturing and employee-related costs [4] - General and administrative expenses fell by 3% year-over-year to $16.9 million [4] - Net collaboration expenses rose to $57.1 million from $11.2 million in the year-ago period, primarily due to reaching a deferral limit on costs related to the Casgevy program [5] Market Sentiment - There has been an upward trend in estimates for CRISPR Therapeutics, with the consensus estimate shifting by 6.45% in the past month [6] - The stock currently holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [8] Industry Comparison - CRISPR Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where Acadia Pharmaceuticals has seen a 13.4% gain over the past month [9] - Acadia reported revenues of $278.63 million for the last quarter, reflecting a year-over-year increase of 11.3% [10]